Leading the Way in Life Science Technologies

GEN Exclusives

More »

Market and Technology Analysis

More »
July 29, 2014

Epigenetic Biomarkers and Clinical Trials

This report presents a snapshot of the epigenetic landscape as it is today.

Epigenetic Biomarkers and Clinical Trials

Epigenetics is currently an amorphous discipline, but there is a definite push toward development and commercialization of diagnostics and therapeutics. [Kenneth Eward/BioGrafx/Photo Researchers]

  • The focus of this GEN Market & Tech Analysis report is to present some of our recent industry tracking of the epigenetics clinical trials and biomarker signatures space.

    Highlights of this report:

    • The epigenetics space represents a rich source of biomarkers and potential therapeutics since the target of action (chromatin) is highly proximal to the site of gene expression.
    • DNA is highly stable ex vivo and offers an excellent starting material for the development of prognostic or predictive biomarker-based tests (potential for epigenetics-based clinical diagnostics development).
    • Clinical trials in the epigenetics space are 50% focused on various cancer classes—indeed this represents the role of cancer as key driver of the epigenetic field, and the current FDA-approved epigenetics-based drugs target various cancer classes.
    • Even though epigenetics is an “amorphous space” we believe that, from a diagnostics and therapeutics perspective, we cannot discount its potential given strong drivers in its favor.
    • Beyond cancer, another area where epigenetics modifications are gaining increasing interest are in the CNS, where epigenetics changes may underlie learning, memory, etc.

Related content